R&D expense · 2023–2025
Heartflow R&D expense
$64.9M+49.2% · FY2025
Heartflow (HTFL) reported $64.9M in R&D expense for fiscal 2025, +49.2% year on year.
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2023–2025 compound annual growth +34.6%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Heartflow R&D expense |url=https://companiesranked.com/en/company/heartflow/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Heartflow R&D expense. CompaniesRanked. https://companiesranked.com/en/company/heartflow/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-heartflow-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Heartflow R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/heartflow/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001464521-26-000042 · March 18, 2026
{{cite web |title=Heartflow R&D expense — 10-K (0001464521-26-000042) |url=https://www.sec.gov/Archives/edgar/data/1464521/000146452126000042/htfl-20251231x10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-18}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.